U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-QSB
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended June 30, 1998
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the transition period from _________ to _________
Commission file 0-24092
POSITRON CORPORATION
(Name of small business issuer in its charter)
Texas
(State or other jurisdiction of incorporation or organization)
I.D. No. 76-0083622
1304 Langham Creek Drive, Suite 310, Houston, Texas 77084
(address of principal executive offices)
Issuer's telephone number: (281) 492-7100
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.
Yes X No
----- -----
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Check whether the registrant filed all documents and reports required
to be filed by Section 12, 13 or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.
Yes No
----- -----
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's classes
of common equity, as of June 30, 1998: 5,159,592
<PAGE>
POSITRON CORPORATION
TABLE OF CONTENTS
Form 10-QSB for the quarter ended June 30, 1998
Page
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Balance Sheets as of December 31, 1997 and
June 30, 1998 F-1
Statements of Operations for the three and
six months ended June 30, 1998 and 1997 F-2
Condensed Statements of Cash Flows for the
six months ended June 30, 1998 and 1997 F-3
Selected Notes to Financial Statements F-4
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operation F-8
Item 6. Exhibits and Reports on Form 8K
Signature Page F-11
Exhibit 27 - Financial Data Schedule F-12
<PAGE>
<TABLE>
POSITRON CORPORATION
BALANCE SHEETS
--------------------
(In thousands, except share data)
<CAPTION>
June 30, December 31,
1998 1997
------- -------
(Unaudited) (Note)
<S> <C> <C>
ASSETS:
Current assets:
Cash and cash equivalents $ 70 $ 160
Accounts receivable, net 386 253
Inventories 331 408
Prepaid expenses 221 131
------- -------
Total current assets 1,008 952
Plant and equipment, net 590 715
------- -------
Total assets $ 1,598 $ 1,667
======= =======
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable, trade $ 1,327 $ 1,573
Accrued liabilities 3,045 3,205
Note payable to an affiliate 767 767
Other note payable 1,152 930
Unearned revenue 60 60
------- -------
Total current liabilities 6,351 6,535
------- -------
Other liabilities 600 245
------- -------
Commitments and contingencies
Stockholders' deficit:
Series A Preferred Stock: $1.00 par value;
8% cumulative, convertible, redeemable;
$1.00 par value; 5,450,000 shares authorized;
1,564,403 and 1,594,999 shares issued and
outstanding at June 30, 1998 and December 31,
1997, respectively 1,564 1,595
Series B Preferred Stock: $1.00 par value,
cumulative, convertible, redeemable; 25,000
shares authorized, issued and outstanding at
June 30, 1998 and December 31, 1997 25 25
Common stock: $0.01 par value; 15,000,000
shares authorized, 5,159,592 and 5,128,990
shares issued and outstanding at June 30,
1998 and December 31, 1997, respectively 52 51
Additional paid-in capital 42,221 42,191
Accumulated deficit (49,200) (48,960)
Treasury stock: 60,156 shares at cost (15) (15)
------- -------
Total stockholders' deficit (5,353) (5,113)
------- -------
Total liabilities and stockholders'
deficit $ 1,598 $ 1,667
======= =======
<FN>
Note: The balance sheet at December 31, 1997 has been derived from the audited
financial statements at that date but does not include all of the information
and footnotes required by generally accepted accounting principles for complete
financial statements. See accompanying notes.
</FN>
F-1
</TABLE>
<PAGE>
<TABLE>
POSITRON CORPORATION
STATEMENTS OF OPERATIONS
------------------------
(In thousands, except share data)
(Unaudited)
<CAPTION>
Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
1998 1997 1998 1997
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Revenues:
Fee per scan $ 199 $ 86 $ 307 $ 208
Service and component 414 391 780 889
----------- ----------- ----------- -----------
Total revenues 613 477 1,087 1,097
----------- ----------- ----------- -----------
Costs of sales and services:
Fee per scan 40 39 60 78
Service, warranty and component 91 82 178 279
----------- ----------- ----------- -----------
Total costs of sales and
services 131 121 238 357
----------- ----------- ----------- -----------
Gross profit 482 356 849 740
----------- ----------- ----------- -----------
Operating expenses:
Research and development 8 141 18 616
Selling and marketing 2 143 16 343
General and administrative 399 343 894 1,247
----------- ----------- ----------- -----------
Total operating expenses 409 627 928 2,206
----------- ----------- ----------- -----------
Income (loss) from operations 73 (271) (79) (1,466)
----------- ----------- ----------- -----------
Other income (expenses):
Other expense -- (48) -- (99)
Interest expense (78) (102) (161) (191)
----------- ----------- ----------- -----------
Total other expense (78) (150) (161) (290)
----------- ----------- ----------- -----------
Net income (loss) $ (5) $ (421) $ (240) $ (1,756)
=========== =========== =========== ===========
Basic and dilutive net loss per
common share $ 0.00 $ (0.09) $ (0.05) $ (0.38)
=========== =========== =========== ===========
Weighted average common shares
outstanding 5,144,291 4,831,653 5,139,191 4,629,255
=========== =========== =========== ===========
<FN>
See accompanying notes
</FN>
F-2
</TABLE>
<PAGE>
<TABLE>
POSITRON CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
----------------------------------
(In thousands)
(Unaudited)
<CAPTION>
Six Months Ended
June 30, June 30,
1998 1997
--------- ---------
<S> <C> <C>
Cash flows from operating activities:
Net loss $ (240) $ (1,756)
Adjustment to reconcile net loss to net
cash used in operating activities (72) 1,438
--------- ---------
Net cash used in operating
activities (312) (318)
--------- ---------
Cash flows from investing activities:
Capital expenditures - (44)
--------- ---------
Net cash used in investing
activities - (44)
--------- ---------
Cash flows from financing activities:
Proceeds from other notes payable, net of
repayments 222 -
Proceeds from conversion of warrants
to common stock - (8)
--------- ---------
Net cash provided by (used in)
financing activities 222 (8)
--------- ---------
Net decrease in cash and cash equivalents (90) (370)
Cash and cash equivalents, beginning
of year 160 382
--------- ---------
Cash and cash equivalents, end of period $ 70 $ 12
========= =========
<FN>
See accompanying notes
</FN>
F-3
</TABLE>
<PAGE>
POSITRON CORPORATION
SELECTED NOTES TO FINANCIAL STATEMENTS
--------------------------------------
1. Basis of Presentation
The accompanying unaudited interim financial statements have been
prepared in accordance with generally accepted accounting principles and
the rules of the U.S. Securities and Exchange Commission, and should be
read in conjunction with the audited financial statements and notes
thereto contained in the Company's Annual Report of Form 10-KSB for the
year ended December 31, 1997. In the opinion of management, all
adjustments, consisting of normal recurring adjustments, necessary for a
fair presentation of financial position and the results of operations for
the interim periods presented have been reflected herein. The results of
operations for interim periods are not necessarily indicative of the
results to be expected for the full year. Notes to the financial
statements which would substantially duplicate the disclosure contained
in the audited financial statements for the most recent fiscal year ended
December 31, 1997, as reported in the Form 10-KSB, have been omitted.
2. Company Operations
Since its inception Positron Corporation (the "Company") has been unable
to sell its POSICAMTM systems in sufficient quantities to be profitable.
Consequently, the Company has sustained substantial losses. Net losses
for the year ended December 31, 1997 and the six months ended June 30,
1998 were $4,455,000 and $240,000, respectively. The Company has an
accumulated deficit of $49,200,000 at June 30, 1998. Due to the sizable
selling prices of the Company's systems and the limited number of systems
sold or placed in service each year, the Company's revenues have
fluctuated significantly year to year.
At June 30, 1998, the Company had cash and cash equivalents in the amount
of $70,000 compared to $160,000 at December 31, 1997. During 1997 and the
first six months of 1998, the Company was unable to meet certain
obligations as they came due. As a result of the Company's liquidity
problem, 1997 salary payments to certain management level employees
totaling approximately $600,000 were unpaid at June 30, 1998.
Additionally, the Company currently has no shares of its Common Stock
available for issuance and all other authorized shares have either been
issued or reserved for issuance in respect of outstanding options and
warrants or convertible securities. The lack of such available shares
significantly restricts the Company's ability to raise capital through
the issuance of additional equity securities. While the Company believes
that its shareholders will approve an increase in the number of
authorized shares of Common Stock at its Annual Meeting of Shareholders,
no assurance can be given that such increase in authorized shares will be
approved by the Company's shareholders.
<PAGE>
3. Net Loss Per Share
Net loss per common share for the three and six months ended June 30,
1998 and 1997 have been computed by dividing net loss by the weighted
average number of shares of Common Stock outstanding during these
periods.
4. Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets or liabilities at the date of the
financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.
5. Income Tax
The difference between the Federal statutory income tax rate and the
Company's effective income tax rate is primarily attributable to
increases in valuation allowances for deferred tax assets relating to net
operating losses.
6. Imatron Transaction
In June 1998, the Company entered into an agreement (the "Imatron
Transaction") with Imatron, Inc. ("Imatron"), whereby Imatron will
acquire a majority ownership of the Company. In conjunction with the
execution of definitive agreements, Imatron began making working capital
advances available to the Company up to $500,000 in order to enable it to
meet a portion of its current obligations. As of June 30, 1998, the
Company had borrowed $468,000. The loan bears interest at 1/2% over the
prime rate, is due March 1, 2000 (with interest being payable monthly),
and is secured by all of the Company's assets.
Under the terms of the agreement, Imatron will acquire a majority
ownership of the outstanding common stock of the Company on a
fully-diluted and as-if-converted basis, excluding out-of-the-money
warrants and options determined at the time of issuance of shares to
Imatron. If such shares were issued to Imatron on June 30, 1998 the
Company would have been obligated to issue nine million shares of common
stock. The Company will receive a nominal cash amount from Imatron in
payment for the shares. Under the planned arrangement, the Company will
remain an independent public company.
F-5
<PAGE>
Imatron, in addition to providing limited working capital financing, has
agreed to support the Company's marketing program particularly with
regard to Imatron's affiliate, Imatron Japan, Inc. by agreeing to make,
after the share issuance closing date, all reasonable efforts to cause
the placement of 10 POSICAM(TM) systems over the next three years. The
Company recently shipped a POSICAM(TM) system to Imatron Japan as the
first delivery under a three-year distribution agreement entered into
last year. Imatron Japan, an affiliate of Imatron, Inc. is a major
distributor for Imatron's Ultrafast CT and for the equipment of certain
other high technology companies. Imatron has a 24 percent minority
interest in Imatron Japan.
Imatron has also agreed to help facilitate the recapitalization of
Positron to support its re-entry into the medical imaging market by using
its best efforts after the share issuance closing date to arrange for
additional third-party equity financing for the Company over an
eighteen-month period in an aggregate amount of not less than $8,000,000.
There can be no assurances, however, that any such sales will actually be
consummated or that Imatron will be able to successfully assist the
Company in raising additional capital.
Consummation of the issuance of shares to Imatron is conditioned upon,
among other things (a) the resignation of each officer of the Company,
(b) the resignation of at least three of the four current directors of
the Company and the appointment of Imatron's nominees to fill such
vacancies, and (c) shareholder approval of an amendment to the Company's
Articles of Incorporation to increase its authorized common stock to at
least 100,000,000 shares. The Company anticipates that the share issuance
to Imatron will close in the third quarter of this year if such
shareholder approval is obtained.
In connection with the above transactions, the Company, Imatron and two
current lenders, Uro-Tech, Ltd. ("Uro-Tech") and ProFutures Bridge
Capital Fund, L.P. ("ProFutures"), entered into certain agreements
whereby (a) ProFutures waived all past defaults and extended the maturity
of its loan ( with a current balance of approximately $706,000) to
October 5, 1998, in return for a $50,000 payment, the issuance of
warrants to purchase 1,150,000 shares of the Company's common stock at
$0.25 per share ( in addition to the issuance of previously bargained for
warrants to purchase an additional 100,000 shares of the Company's stock
at $0.25 per share), and minimum loan repayments of $50,000 for each of
the months of April, May, June and July, 1998 and $100,000 for each of
the months of August and September 1998 (b) Imatron agreed to subordinate
its loan to ProFuture's loan, (c) Uro-Tech agreed to subordinate its loan
(with a current balance of approximately $767,000 plus accrued interest
payable of approximately $260,000 at June 30, 1998) to Imatron's loan,
and (d) ProFutures's and Imatron agreed that all amounts above the first
$1,000,000 of any third party equity financing obtained by Imatron would
be applied equally to reduce the Company's debt to both ProFutures and
Imatron.
F-6
<PAGE>
If the Imatron Transaction is not completed, or if the Imatron
Transaction is completed and Imatron is unsuccessful in its efforts to
raise capital for the Company, management believes the Company may be
unable to continue as a going concern and that the Company's assets may
be seized by its secured creditors.
F-7
<PAGE>
POSITRON CORPORATION
(Form 10-QSB for the six months ended June 30, 1998)
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion should be read in conjunction with the Company's
unaudited financial statements and related notes thereto included in this
quarterly report and in the audited Financial Statements and Managements
Discussion and Analysis of Financial Condition and Results of Operations
("MD&A") contained in the Company's 10-KSB for the year ended December 31, 1997.
Certain statements in the following MD&A are forward looking statements. Words
such as "expects", "anticipates", "estimates" and similar expressions are
intended to identify forward looking statements. Such statements are subject to
risks and uncertainties that could cause actual results to differ materially
from those projected. Such risks and uncertainties are set forth below and under
"Information Regarding and Factors Affecting Forward Looking Statements".
Comparison of the Results of Operations for the six months ended June 30, 1998
and 1997.
During the six months ended June 30, 1998, the Company continued to experience
deterioration in its financial condition; however, the Company's net loss
decreased $1,516,000 from ($1,756,000) for the six months ended June 30, 1997 to
($240,000) for the six months ended June 30, 1998. This decrease in net loss is
primarily the result of significant staff reductions and efforts to curtail
costs.
The Company generated no revenue from system sales during the first six months
of 1998 or 1997. Fee per scan revenue increased $99,000 from $208,000 during the
first six months of 1997 to $307,000 for the first six months of 1998 due
primarily to a greater number of scans being performed by Buffalo Cardiology
during the six months ended June 30, 1998. In addition, there was a decrease in
service and component sales revenue of $109,000 during the same period due to
less service work performed during the six months ended June 30, 1998. This
reduction in service work is directly attributable to staff reductions and
normal fluctuations in service.
Gross profit during the first six months of 1998 was $849,000 compared to
$740,000 for the six months ended June 30, 1997. This increase in gross profit
of $109,000 is due primarily to lower service costs brought on by staff
reductions during the six months ended June 30, 1998.
F-8
<PAGE>
Total operating expense decreased approximately $1,278,000 or 58% from
$2,206,000 for the six months ended June 30, 1997 to $928,000 for the six months
ended June 30, 1998. The decrease primarily results from significant staff
reductions and related reductions in administrative overhead costs during the
six months ended June 30, 1998.
Interest expense decreased from $191,000 for the six months ended June 30, 1997
to $161,000 for the six months ended June 30, 1998 due primarily to the
reduction in the Company's debt level in the first six months of 1998 as
compared to the first six months of 1997.
Financial Condition
Since its inception the Company has been unable to sell POSICAM(TM) systems at
quantities sufficient to be profitable. Consequently, the Company has sustained
substantial losses. Net losses for the year ended December 31, 1997 and the six
months ended June 30, 1998 were ($4,455,000) and ($240,000), respectively. At
June 30, 1998, the Company had an accumulated deficit of approximately
$49,200,000. Due to the sizable prices of the Company's systems and the limited
number of systems sold or placed in service each year, the Company's revenues
have fluctuated significantly year to year.
At June 30, 1998, the Company had cash and cash equivalents in the amount of
$70,000 compared to $160,000 at December 31, 1997. Throughout much of 1997 and
the first half of 1998, the Company has been unable to meet certain of its
obligations as they came due. As a result of the Company's liquidity problem,
1997 salary payments and other benefits to certain management level employees
totaling approximately $600,000 were unpaid at June 30, 1998.
The Company's only current plan with regard to its liquidity problems is to
attempt to complete the Imatron transaction discussed in Selected Notes to the
Financial Statements. If the Imatron Transaction is not completed, or if the
Imatron Transaction is completed and Imatron is unsuccessful in its efforts to
raise capital for the Company, management believes the Company may be unable to
continue as a going concern and that the Company's assets may be seized by its
secured creditors.
The Company currently has no shares of Common Stock available for issuance and
all authorized shares have either been issued or reserved for issuance in
respect of outstanding options and warrants or convertible securities. The lack
of such available shares significantly restricts the Company's ability to raise
additional capital through the sale of equity securities. The Company believes
that its shareholders will approve an increase in the number of authorized
common shares at its Annual Meeting; however, no assurance can be given that
such additional shares will be authorized in adequate time to allow the Company
to issue such equity securities.
F-9
<PAGE>
Impact of the Year 2000
The year 2000 issue is the result of computer programs being written using two
digits rather than four to define the applicable year. Any of the Company's
computer programs that have time sensitive software may recognize a date using
"00" as the year 1900 rather than the year 2000. This could result in a system
failure or miscalculation causing disruption of business activities.
Based on ongoing assessments, the Company believes that no significant
modifications of existing computer software will be required. The Company
believes that its computer systems will function properly with respect to dates
in the year 2000 and thereafter. The Company also believes that costs related to
the Year 2000 issue will not be significant.
The Company is currently assessing its relationships with significant suppliers
and major customers to determine the extent to which the Company is vulnerable
to any third party's failure to remedy their own Year 2000 issues. Based on
preliminary assessments, management believes that significant exposure does not
exist with respect to third parties.
Information Regarding and Factors Affecting Forward Looking Statements
The Company is including the following cautionary statement in this Quarterly
Report on Form 10-QSB to make applicable and take advantage of the safe harbor
provision of the Private Securities Litigation Reform Act of 1995 for any
forward-looking statements made by, or on behalf of the Company. Forward-looking
statements include statements concerning plans, objectives, goals, strategies,
future events or performance and underlying assumptions and other statements
which are other than statements of historical facts. Certain statements
contained herein are forward-looking statements and, accordingly, involve risks
and uncertainties which could cause actual results or outcomes to differ
materially from those expressed in the forward-looking statements. The Company's
expectations, beliefs and projections are expressed in good faith and are
believed by the Company to have a reasonable basis, including without
limitations, management's examination of historical operating trends, data
contained in the Company's records and other data available from third parties,
but there can be no assurance that management's expectation, beliefs or
projections will result, or be achieved, or be accomplished.
F-10
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
POSITRON CORPORATION
(Registrant)
Date: September 17, 1998 /s/ Gary B. Wood, Ph.D.
------------------------
Chief Executive Officer
(Duly Authorized Officer and
Principal Accounting Officer)
F-11
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
The schedule contains summary financial information extracted from Positron
Corporation's consolidated condensed statements of income and consolidated
condensed balance sheets and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<CIK> 0000844985
<NAME> Positron Corporation
<MULTIPLIER> 1,000
<CURRENCY> U.S. Dollars
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> Dec-31-1998
<PERIOD-START> Jan-01-1998
<PERIOD-END> Jun-30-1998
<EXCHANGE-RATE> 1
<CASH> 70
<SECURITIES> 0
<RECEIVABLES> 1613
<ALLOWANCES> 1227
<INVENTORY> 331
<CURRENT-ASSETS> 1008
<PP&E> 2419
<DEPRECIATION> 1829
<TOTAL-ASSETS> 1598
<CURRENT-LIABILITIES> 6351
<BONDS> 0
0
1589
<COMMON> 52
<OTHER-SE> (6994)
<TOTAL-LIABILITY-AND-EQUITY> 1598
<SALES> 0
<TOTAL-REVENUES> 1087
<CGS> 238
<TOTAL-COSTS> 1166
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 161
<INCOME-PRETAX> (240)
<INCOME-TAX> 0
<INCOME-CONTINUING> (240)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (240)
<EPS-PRIMARY> (0.05)
<EPS-DILUTED> (0.05)
</TABLE>
